Please type a plus sign (+) inside this box →	+	
---	---	--

PTO/SB/08A (10-96)
pproved for use through 10/31/99. OMB 0651-0031
atent and mark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Mark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known					
Application Number	09/688,851	RECEIN	VE F		
Filing Date	10/16/2000	TILOLI			
First Named Inventor	Jeffrey M. Staub				
Group Art Unit	1639	MAY 0 3	002		
Examiner Name	G.Helmer				

15868/02

TECH CENTER 600/2900

U.S. PATENT DOCUMENTS Pages, Columns, Lines, U.S. Patent Document Date of Publication of Where Relevant Name of Patentee or Applicant Cite Cited Document Passages or Relevant Kind Code of Cited Document Number No.1 nitials' MM-DD-YYYY Figures Appear (if known)

Attorney Docket Number

	FOREIGN PATENT DOCUMENTS								
Examiner Cite		Foreign Patent Document Kind Code ⁵ Number ⁴ (if known)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
20/6-	B1	WO	97/41228	A2	Gordon-Kamm	11/06/1997			
ath	B2		01/21768	A1	P. Maliga	03/29/2001		\perp	
0								1	
								+	
		<u> </u>						+	
		<u> </u>						1	
 	<u> </u>								
		 							

Examiner Signature Ally	Date Considered	4	30	02

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include dopy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ı]
Ī	
	•
<	•
T	ì
-	-

nder the Pape						n unless it contains a valid OMB mplete if Known	
		orm 1449B/PTO			Application Number	09/688,851	
INF	ORI	MATION	DISCLOS	URE	Filing Date	10/16/2000	
			BY APPLIC		First Named Inventor	Jeffrey M. Staub	
					Group Art Unit	1638	
(c)	(u	se as many si	heets as necessary	/)	Examiner Name	G. Helmer	
of sine at	1		of 1		Attorney Docket Number	15868/02	
2							
			OTHER PRIOR	R ART N	ION PATENT LITERATUR	RE DOCUMENTS	
Examiner Initials	Cite No.1	Incluitem (ude name of the auth book, magazine, journ	nat serial syn	L LETTERS), title of the article (value) inposium, catalog, etc.), date, pag ty and/or country where publishe	e(s), volume-issue number(s),	
- dh		DALE E.C.	ET AL, "Gene tr	ansfer with	subsequent removal of th	e selection gene from the	host
9	C1	genome," Ph	NAS USA, Natio	nal Acaden	ny of Science (Washingto	n), p. 10558-62, (Decemb	oer 199
		İ				1 to attend to allow the	.11a
1 0/1	.	DALE E.C	. ET AL, "Intra-	and interr	nolecular site-specific re	combination in plant cc	/115 ~ /100
	\ I			D.1	L'arrest Come Electron	(Ametardam) 0 n 70-8	5 /199
7	VC2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
120	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
70	€2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
70	€2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	<u>5, (199</u>
70	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
70	€2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
70	€2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
7	€2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
- B	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
7	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
70	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
- D	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
- By	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
- B'	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
- B	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199
-5°	C2	mediated b	y bacteriophage	P1 recom	binase," Gene, Elsevier	(Amsterdam), 9: p. 79-8	5, (199

Examiner Signature Signature	Date Considered	5	30	01
orgination of the contract of				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.